Preventing Cancer, No Bones About It

For a pharmaceutical company, the only thing better than having a drug with more than $1 billion in annual sales is getting it approved to treat more patients.

Eli Lilly (NYSE: LLY  ) scored a second indication for its osteoporosis drug EVISTA when the FDA approved it to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis or women who are at high risk for invasive breast cancer.

EVISTA is a selective estrogen receptor modulator (SERM), which acts differently on estrogen receptors in different parts of the body. EVISTA appears to prevent breast cancer by blocking estrogen from stimulating the growth of tumor cells.

The new indication is coming at the perfect time. Merck's (NYSE: MRK  ) competing osteoporosis drug, Fosamax, is going off-patent in February, so the fact that it prevents invasive breast cancer might keep some EVISTA patients from switching to cheaper generic versions of Fosamax that are sure to flood the market.

Being able to market the drug for the prevention of breast cancer should also help EVISTA compete against Roche's and GlaxoSmithKline's (NYSE: GSK  ) BONIVA, as well as Wyeth's (NYSE: WYE  ) bazedoxifene, which Wyeth is hoping to seek approval on.

While the approval will certainly help EVISTA compete against other osteoporosis drugs, it's not clear how many patients will take the drug just for the prevention aspect. The new approval doesn't increase the patient population by that much -- there are many more women with osteoporosis than those at risk for invasive breast cancer. Given that the drug will still contain a "black box" warning regarding patients with a past history of venous thromboembolism or a risk of stroke, doctors may be a little leery of prescribing it strictly for its preventative aspects.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 536927, ~/Articles/ArticleHandler.aspx, 10/26/2016 7:47:12 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
LLY $76.76 Down -0.99 -1.27%
Eli Lilly and Co. CAPS Rating: ***
GSK $40.34 Up +0.02 +0.05%
GlaxoSmithKline CAPS Rating: ***
MRK $60.87 Down -1.08 -1.74%
Merck and Co. CAPS Rating: ****
WYE.DL $0.00 Down +0.00 +0.00%
Wyeth CAPS Rating: ***